Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Doskaliuk (Ivano-Frankivsk, Ukraine), L. Zaiats (Ivano-Frankivsk, Ukraine), R. Yatsyshyn (Ivano-Frankivsk, Ukraine). Experimental modeling of lung involvement due to systemic sclerosis.. 749

Member's Comments

No comment yet.

Related content which might interest you: Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001 Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Pulmonary involvement in systemic sclerosis Source: Eur Respir Monogr 2019; 86: 90-105 Year: 2019 The genetics of systemic sclerosis Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Pulmonary functions in systemic sclerosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 95s Year: 2006 Applying machine learning and pulmonary function data to detect interstitial lung disease in systemic sclerosis. Source: International Congress 2017 – Best abstracts in lung function Year: 2017 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 543s Year: 2005 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pulmonary function in progressive systemic sclerosis Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Interstitial lung involvement in systemic sclerosis. Correlation of HRCT and lung function tests Source: Eur Respir J 2004; 24: Suppl. 48, 487s Year: 2004 Survival and prognostic factors in progressive systemic sclerosis with lung involvement Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Interstitial lung disease in systemic sclerosis: where do we stand? Source: Eur Respir Rev 2015; 24: 411-419 Year: 2015